$0.42+6.0%Nov 13 close
Reported results on November 12, 2026; they are not in these figures yet.
Figures through June 30, 2026, from the 10-Q filed August 13, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.2M | $1.4M | -15.10% |
| Profit | -$2.6M | -$1.7M | -48.30% |
| Profit per share | -$0.20 | -$0.79 | +74.68% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Ensysce Biosciences, Inc. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Ensysce is a fundamentally different company today than it was at the start of the year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Ensysce Biosciences is a clinical-stage biotechnology company developing novel neuroplastogenic therapies using psychedelics that go beyond mood disorders and address the root cause of chronic pain through central nervous system modulation. The Company is also developing a new class of highly novel opioids for the treatment of severe pain while minimizing the risk of both drug abuse and overdose.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Ensysce Biosciences, Inc.’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.